Devimistat
- Generic Name
- Devimistat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28O2S2
- CAS Number
- 95809-78-2
- Unique Ingredient Identifier
- E76113IR49
- Background
Devimistat (CPI-613) has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.
EMA Grants Orphan Drug Designation to Devimistat for Refractory Burkitt's Lymphoma
• The European Medicines Agency (EMA) has granted orphan drug designation to Rafael Pharmaceuticals' devimistat for treating refractory or relapsed Burkitt's lymphoma.
• Burkitt's lymphoma, a rare and aggressive form of non-Hodgkin's lymphoma, disproportionately affects children, representing up to 30% of pediatric NHL cases.
• Devimistat targets the mitochondrial tricarboxylic acid cycle, crucial for tumor cell proliferation, and has received multiple orphan drug designations from both EMA and FDA.
• A Phase 2 trial is underway to investigate devimistat's efficacy in relapsed or refractory Burkitt's lymphoma, offering hope for patients with limited treatment options.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath